AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KAUG 211 min read$MGRX

MANGOCEUTICALS, INC. (MGRX): Termination of a Material Definitive Agreement

MANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. Termination of Business Combination Agreement with Nuclea Energy Inc. On August 19, 2026, Mangoceuticals, Inc. (the “Company” or “MGRX”) and Nuclea Energy Inc. (“Nuclea”) mutually agreed to terminate that certain Business

Original reporting
SEC EDGAR 8-K
Published Aug 21, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$MGRX
Bearish
medium confidence
Mentioned
$MGRX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MGRXBearishLow
01

Why it matters

The mutual termination removes the anticipated merger premium and may trigger a price correction, while also freeing the company from the financing condition.

02

Market read

Primary disclosure of a failed merger for a micro‑cap biotech, likely causing short‑term volatility.

03

What to watch

Potential cash burn from ongoing operations and any remaining assets could support a future standalone strategy.

Relevance 6/10Novelty 6/10Timing: filed Aug 21 2026

Background

Mangoceuticals (Nasdaq: MGRX) had announced a planned business combination with Nuclea Energy in July 2026, contingent on a $15 M PIPE financing that was not secured.

Company-level read

Ticker impact

$MGRXBearishMedium confidence
Context

Mangoceuticals terminated its Business Combination Agreement with Nuclea Energy, ending the planned merger.

Expected impact

Potential short-term decline as merger premium disappears.

Evidence & confidence

Deal collapse eliminates expected synergies and financing, likely leading to sell pressure.

Market effects

Sector

Spillover to other SPAC‑style merger targets in biotech.

Regional

Limited to U.S. biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

If the termination was due to unfavorable PIPE terms, the company may pursue a better partner later.

Key entities

  • Company
    Mangoceuticals, Inc.

    Biotech SPAC filing the 8‑K termination.

  • Company
    Nuclea Energy Inc.

    Counterparty in the terminated business combination.

Read at source← All news

Related articles

OCT 1
$MGRXLow

MANGOCEUTICALS, INC. (MGRX): Completion of Acquisition or Disposition of Assets

MANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No Issuan

SEC EDGAR 8-K2 min
AUG 6
$MGRXMed

Why is Mangoceuticals stock surging today?

Mangoceuticals (MGRX) shares rose 31.9% pre-open to $0.5612 after its merger partner, Nuclea Energy, said it reached a regulatory and siting milestone via a memorandum of understanding to locate the Morpheus microreactor at Utah’s San Rafael Energy Lab. The MOU supports a planned business combination that remains subject to approvals, with earnings expected around Aug. 13.

investing.com3 min
AUG 6
$MGRXMed

Mangoceuticals (MGRX) Stock Jumps Over 49% After Hours: Here's Why Mangoceuticals Stock Jumps 49% After H

Mangoceuticals (MGRX) shares rose more than 49% after hours after the company said it signed an MOU with Nuclea Energy to explore siting a nuclear test reactor at Utah’s San Rafael Energy Lab to support Nuclea’s Morpheus microreactor. Mangoceuticals and Nuclea have a July 30 business combination agreement, pending approvals. MGRX received a 180-day Nasdaq bid-price extension to Feb. 1, 2027.

benzinga.com4 min
JUL 31
$MGRXMedAI 8/10

Mangoceuticals To Merge With Nuclea Energy, Advancing Nuclear Microreactor; Stock Up

Mangoceuticals (MGRX) signed a definitive deal to combine with Nuclea Energy to advance Nuclea’s Morpheus nuclear microreactor to public markets. Nuclea shareholders will receive exchangeable shares in a new Mangoceuticals subsidiary, exchangeable one-for-one into MGRX common stock, subject to Nasdaq limits. MGRX closed at $0.29, down 46.88%, after a $0.16 to $2.75 52-week range.

rttnews.com4 min